Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923

Journal of Clinical Oncology

Volumn 20, Issue 19, 2002, Pages 3947-3955

  Ardizzoni, Andrea ^a   Tjan Heijnen, Vivianne C G ^a   Postmus, Pieter E ^a   Buchholz, Erica ^a   Biesma, Bonne ^a   Karnicka Mlodkowska, Hanna ^a   Dziadziuszko, Rafal ^a   Burghouts, Jos ^a   van Meerbeeck, Jan P ^a   Gans, Steven ^a   Legrand, Catherine ^a   Debruyne, Channa ^a   Giaccone, Giuseppe ^a   Manegold, Christian ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG RESPONSE; EUROPE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

EID: 0036788622     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.069     Document Type: Article

References (26)

1. Ihde DC: Small cell lung cancer: State-of-the-art therapy 1994. Chest 107:243-248, 1995 (suppl)
2. Ellias AD, Cohen BF: Dose-intensive therapy in lung cancer, in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells (ed 2). Baltimore. MD, Williams & Wilkins, 1995, pp 824-846
3. Woll P, Thatcher N, Lomax L, et al: Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 19:712-719, 2001
4. Leyvraz S, Perey L, Rosti G, et al: Multiple courses of high-dose ifosfamide, carboplatin and etoposide with peripheral-blood progenitors cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17:3531-3539, 1999
5. Ihde DC, Mulshine JL, Kramer BS, et al: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
6. Johnson DH, Einhorn LH, Birch K, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small-cell lung cancer: A phase III study trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731-1738, 1987
7. Arriagada R, Le Chevalier T, Pignon JP, et al: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Eng J Med 329:1848-1852, 1993
8. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
9. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
10. Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
11. Gurney H, Dodwell D, Thatcher N, et al: Escalating drug delivery in cancer therapy: A review of concepts and practice. II. Ann Oncol 4:103-115, 1993
12. Ardizzoni A, Sertoli MR, Corcione A, et al: Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: A phase II non-randomized study. Eur J Cancer 26:937-941. 1990
13. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony stimulating factor (GM-CSF) allows acceleration and dose-intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
14. Thatcher N, Clark PI, Smith DB, et al: Increasing the planned dose-intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony stimulating factor (G-CSF; filgrastim) in the treatment of small-cell lung cancer (SCLC). J Clin Oncol 7:293-299, 1995
15. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995
16. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 9:499-508, 1991
17. Giaccone G, Dalesio O, McVie GJ, et al: Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. J Clin Oncol 11:1230-1240, 1993
18. Ardizzoni A, Pennucci MC, Danova M, et al: Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. Br J Cancer 73:1141-1147, 1996
19. Tjan-Heijnen VCG, Postmus PE, Ardizzoni A, et al: Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359-1368, 2001
20. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Cox DR, Snell E: Analysis of Binary Data (ed 2). London, United Kingdom, Chapman & Hall, 1989
23. Pujol JL, Douillard JY, Riviere A, et al: Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small cell lung cancer: A multicenter randomized phase III study. J Clin Oncol 15:2082-2089, 1997
24. Steward WP, von Pawel J, Gatzemeier U, et al: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 16:642-650, 1998
25. Thatcher N, Girling DJ, Hopwood P, et al: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol 18:395-404, 2000
26. Sculier JP, Peasman M, Lecomte J, et al: A three-arm phase III randomised trial assessing in patients with extensive-disease small-cell lung cancer accelerated chemotherapy with support of haematological growth factors or oral antibiotics. Br J Cancer 85:1444-1451, 2001